Kiromic BioPharma (OTCQB: KRBP) has reported a series of promising developments from its Deltacel-01 Phase 1 clinical trial, which is focused on evaluating Deltacel (KB-GDT-01), the Company’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy. This trial targets patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies.’
Interim Results from Part 1 of the Deltacel-01 Trial’
According to the most recent updates, Kiromic BioPharma has released interim results that nearly conclude Part 1 of the Deltacel-01 trial. This part of the trial has evaluated the efficacy and safety of Deltacel in five patients with advanced NSCLC. While specific quantitative data are not yet fully disclosed, the data available revealed encouraging results concerning patient progression, indicating a potential therapeutic benefit of the GDT therapy.
Advancement to Part 2 The Expansion Phase’
In another significant update, Kiromic BioPharma announced plans to advance to the Expansion Phase (Part 2) of the Deltacel-01 trial. This progression follows a positive assessment by the Deltacel-01 Safety Monitoring Committee (SMC), which convened on July 16th. The SMC reviewed the safety and efficacy data collected thus far and deemed the findings favorable, confirming an optimal dose for the next phase. This endorsement by the SMC underscores the potential of Deltacel therapy and allows further testing on a broader patient cohort.
Follow-Up Results: Signs of Stability’
Further follow-up results have been reported from the second, third, and fourth patients enrolled in the trial. Significantly, the third and fourth patients demonstrated disease stability, which is notably positive for individuals with stage 4 metastatic NSCLC, a condition often characterized by rapid progression. These updates reinforce the potential effectiveness of Deltacel as a viable treatment option for patients who have exhausted other therapeutic avenues.
Conclusion’
Kiromic BioPharma’s Deltacel-01 clinical trial yields promising interim results in its early stages, with encouraging signals of disease stability in several patients. These developments bolster the case for Deltacel as an innovative therapeutic option for advanced NSCLC. As the trial enters its Expansion Phase, the medical community will be closely monitoring ongoing results to validate these initial findings.
Comments